TNFSF13B and systemic lupus erythematosus: Drugs blocking BLyS activity (belimumab), and more recently, the type I IFN receptor subunit 1 (anifrolumab), have reduced disease activity in patients with SLE in large clinical trials and are now approved therapies for SLE treatment (14, 16).